Influenza News and Research

Latest Influenza News and Research

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program.

2 Jul 2015

Mortality rates vary depending on socioeconomic differences among areas in Europe

For a number of years now, scientific literature has questioned whether mortality rates depend on socioeconomic differences among the population. Recently, a new study carried out in 15 European cities - including Barcelona and Madrid - detected inequalities for the majority of causes, concluding that higher levels of poverty are associated with higher mortality rates and there is a great deal of variation among areas.

2 Jul 2015

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans.

2 Jul 2015

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax Pharmaceuticals Ltd. today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine.

30 Jun 2015

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed.

26 Jun 2015

Larrea Biosciences merged into Gordian Holdings

Larrea Biosciences has been merged into Gordian Holdings, Inc. "Marshalling the Body's best Offense and Defense against Disease, Its own Immune System, through Immunotherapy." Gordian Holdings obtained the rights from OnkologixRx, Inc., for the Markets in China and North America.

25 Jun 2015

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

24 Jun 2015

Generic heart disease drugs show promise in patients affected by Ebola virus

Generic medications used frequently in the management of heart disease patients also have the potential to bolster the immune systems of patients with Ebola virus and some other life-threatening illnesses, researchers report this week in mBio, the online open-access journal of the American Society for Microbiology.

23 Jun 2015

New research examines antibiotic choice for treating children with community-acquired pneumonia

New Vanderbilt-led research shows hospitals are doing a better job of using antibiotics less commonly associated with antibiotic resistance to treat children hospitalized with community-acquired pneumonia (CAP).

23 Jun 2015

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

To predict how a seasonal influenza epidemic will spread across the United States, one should focus more on the mobility of people than on their geographic proximity, a new study suggests.

19 Jun 2015

Public health experts outline strategies for managing MERS-CoV outbreak

The ongoing outbreak in the Republic of Korea (South Korea) is an important reminder that the Middle East respiratory virus (MERS-CoV) requires constant vigilance and could spread to other countries including the United States. However, MERS can be brought under control with effective public health strategies, say two Georgetown University public health experts.

18 Jun 2015

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.

17 Jun 2015

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

16 Jun 2015

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Infection control experts to convene at IPAC Canada conference

Infection control experts from across the country will meet in Victoria from June 14-17 at the Victoria Conference Centre for educational workshops and conference.

9 Jun 2015

St. Michael's Hospital researchers find novel method to combat flu virus

The flu kills hundreds of thousands of people around the world every year, yet there is essentially only one class of drugs to fight the ever-changing virus. Cases of flu resistant to this class of drugs have already been reported and researchers worry a completely new strain of flu could evolve, leading to a pandemic like the one in 1918 that killed approximately 50 million people.

8 Jun 2015

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Protein Sciences Corporation announced that in a rare move, the FDA is granting exclusivity to Flublok for a period of 12 years. Flublok is the first vaccine awarded this very important status, demonstrating Flublok as a unique and game changing influenza vaccine.

3 Jun 2015

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

Scientists recognize that 90% of pathogens actually enter the body through the mucosa and secondly, we have evolved a mucosal defense system that can be used to defend against disease...

1 Jun 2015

BiondVax provides update on financial results for first quarter 2015

1 Jun 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Invetech, a leader in instrument development, custom automation, and contract manufacturing, and Vaxxas, a biotechnology start-up and developer of the Nanopatch™ needle-free drug delivery technology, have been named winners of the 2015 Good Design Award for development of the Nanopatch Jet Coating Instrument, an advanced technology platform to support needle-free dermal drug delivery research and product development. The award was announced last evening at the Good Design Awards Gala Night held in Sydney, Australia.

1 Jun 2015

Influenza News and Research

Latest Influenza News and Research

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

Mortality rates vary depending on socioeconomic differences among areas in Europe

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Larrea Biosciences merged into Gordian Holdings

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

Generic heart disease drugs show promise in patients affected by Ebola virus

New research examines antibiotic choice for treating children with community-acquired pneumonia

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

Public health experts outline strategies for managing MERS-CoV outbreak

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Infection control experts to convene at IPAC Canada conference

St. Michael's Hospital researchers find novel method to combat flu virus

FDA grants exclusivity to Flublok influenza vaccine for 12 years

Vaccines - a needle-free future? An interview with Thomas Johnston and Dr. Kees Leenhouts, Mucosis

BiondVax provides update on financial results for first quarter 2015

Nanopatch Jet Coating drug delivery platform wins 2015 Good Design Award

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Influenza News and Research

Latest Influenza News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in